Overview

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
AZD1656 in Transplantation with Diabetes tO PromoTe Immune TOleraNce: a single site, placebo-controlled, double-blind randomised clinical trial of AZD1656 in renal transplant patients with Type 2 diabetes
Phase:
Phase 2
Details
Lead Sponsor:
Queen Mary University of London
Collaborator:
AstraZeneca